Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 6/20 | 0.45 |
| ▸ | PGR | P06401 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4163146 | 0.88 | NR3C1 (0.53) | NR3C1PGRNR3C2AR | |
| SCHEMBL4176230 | 0.82 | NR3C1 (0.46) | RAB9ANR3C1PGRNPC1NR3C2 | |
| SCHEMBL4173274 | 0.81 | NR3C1 (0.50) | RAB9ANR3C1PGRNPC1NR3C2 | |
| SCHEMBL4167078 | 0.81 | NR3C1 (0.47) | RAB9ANR3C1PGRNPC1NR3C2 | |
| SCHEMBL4168013 | 0.81 | HPGD (0.48) | RAB9ANR3C1PGRSMN1; SMN2NPC1 | |
| SCHEMBL4167696 | 0.80 | NR3C1 (0.49) | RAB9ANR3C1PGRALDH1A1NR3C2 | |
| SCHEMBL4178107 | 0.79 | NR3C1 (0.45) | RAB9ANR3C1PGRSMN1; SMN2NPC1 | |
| SCHEMBL13909324 | 0.79 | NR3C1 (0.43) | RAB9ANR3C1PGRNPC1NR3C2 | |
| SCHEMBL4173269 | 0.79 | NR3C1 (0.50) | RAB9ANR3C1PGRSMN1; SMN2NPC1 | |
| SCHEMBL4167811 | 0.79 | NR3C1 (0.48) | RAB9ANR3C1PGRSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | disclosed |
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | disclosed |
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | NR5A1, CYP19A1, GPER1 | RAB9A 4606/4885NR3C1 60/4885PGR 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.